Sugi Predict

Sugi Predict / Targets / MRPL37

MRPL37

Large ribosomal subunit protein mL37 · Q9BZE1 · MRPL37 on Sugi Atlas →

0 patent compounds predicted against MRPL37, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MRPL37 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea PHASE3COMPLETED
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) PHASE1/PHASE2COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma nanCOMPLETED
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide nanRECRUITING
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Autophagy Bladder Cancer nanUNKNOWN
Serum NGAL IN Patients With Multiple Myeloma nanUNKNOWN
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects) nanUNKNOWN
Human Adaptation to High Altitude nanUNKNOWN
Phenotype and Etiology of Pallister-Hall Syndrome nanCOMPLETED
Exercise-induced Epigenetic Adaptations nanCOMPLETED
Apelin12 in Acne Vulgaris nanUNKNOWN
PROOF: Pancreatitis-associated Risk Of Organ Failure nanCOMPLETED
RibOSE - Glucose and Resistance Exercise Training nanCOMPLETED
Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE) nanACTIVE_NOT_RECRUITING
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes nanRECRUITING
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MRPL37 binder may also engage these)

ProteinNameSimilarity
A4FUC0 — 1.000 A4FUC0 →
Q921S7 — 1.000 Q921S7 →
Q6AXT0 — 0.997 Q6AXT0 →
Q5ZI69 — 0.992 Q5ZI69 →
P82924 — 0.988 P82924 →
Q9NP92 — 0.983 Q9NP92 →
Q9D0G0 — 0.978 Q9D0G0 →
Q9CZW2 — 0.977 Q9CZW2 →
P12540 — 0.976 P12540 →
P12539 — 0.975 P12539 →
Q8BMJ7 — 0.975 Q8BMJ7 →
Q6AYQ6 — 0.974 Q6AYQ6 →
F1PLN3 — 0.974 F1PLN3 →
Q6GLY5 — 0.974 Q6GLY5 →
A1A4J7 — 0.974 A1A4J7 →
Q6PFH3 — 0.973 Q6PFH3 →
Q9NVM9 — 0.973 Q9NVM9 →
Q99N84 — 0.972 Q99N84 →
O88480 — 0.972 O88480 →
Q5ZHV2 — 0.972 Q5ZHV2 →
B3LVQ1 — 0.972 B3LVQ1 →
Q9D2K4 — 0.972 Q9D2K4 →
Q99K74 — 0.971 Q99K74 →
Q3SYW0 — 0.971 Q3SYW0 →
Q3UHQ6 — 0.971 Q3UHQ6 →
Q91ZD4 — 0.971 Q91ZD4 →
Q6DKG0 — 0.970 Q6DKG0 →
A0A1B0GVH7 — 0.970 A0A1B0GVH7 →
Q8QZV7 — 0.970 Q8QZV7 →
O75182 — 0.970 O75182 →